X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs PIRAMAL ENTERPRISES - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER PIRAMAL ENTERPRISES PFIZER/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 36.4 10.4 349.8% View Chart
P/BV x 5.4 1.8 298.8% View Chart
Dividend Yield % 0.6 0.9 70.0%  

Financials

 PFIZER   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    PFIZER
Mar-18
PIRAMAL ENTERPRISES
Mar-18
PFIZER/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2,3653,083 76.7%   
Low Rs1,6251,902 85.4%   
Sales per share (Unadj.) Rs430.3589.7 73.0%  
Earnings per share (Unadj.) Rs78.7284.0 27.7%  
Cash flow per share (Unadj.) Rs93.2310.5 30.0%  
Dividends per share (Unadj.) Rs20.0025.00 80.0%  
Dividend yield (eoy) %1.01.0 100.0%  
Book value per share (Unadj.) Rs586.51,467.0 40.0%  
Shares outstanding (eoy) m45.75180.27 25.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.64.2 109.7%   
Avg P/E ratio x25.38.8 288.9%  
P/CF ratio (eoy) x21.48.0 266.7%  
Price / Book Value ratio x3.41.7 200.2%  
Dividend payout %25.48.8 288.7%   
Avg Mkt Cap Rs m91,271449,332 20.3%   
No. of employees `0002.66.8 38.4%   
Total wages/salary Rs m3,14319,881 15.8%   
Avg. sales/employee Rs Th7,484.815,535.6 48.2%   
Avg. wages/employee Rs Th1,195.02,905.4 41.1%   
Avg. net profit/employee Rs Th1,369.17,482.5 18.3%   
INCOME DATA
Net Sales Rs m19,685106,310 18.5%  
Other income Rs m1,1432,595 44.0%   
Total revenues Rs m20,828108,906 19.1%   
Gross profit Rs m5,00351,599 9.7%  
Depreciation Rs m6634,773 13.9%   
Interest Rs m429,783 0.0%   
Profit before tax Rs m5,47919,638 27.9%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,878-28,764 -6.5%   
Profit after tax Rs m3,60151,203 7.0%  
Gross profit margin %25.448.5 52.4%  
Effective tax rate %34.3-146.5 -23.4%   
Net profit margin %18.348.2 38.0%  
BALANCE SHEET DATA
Current assets Rs m24,167118,154 20.5%   
Current liabilities Rs m9,544462,260 2.1%   
Net working cap to sales %74.3-323.7 -22.9%  
Current ratio x2.50.3 990.6%  
Inventory Days Days5527 207.3%  
Debtors Days Days2947 61.7%  
Net fixed assets Rs m9,514113,727 8.4%   
Share capital Rs m458361 126.9%   
"Free" reserves Rs m26,375264,093 10.0%   
Net worth Rs m26,832264,454 10.1%   
Long term debt Rs m25242,206 0.0%   
Total assets Rs m36,900726,834 5.1%  
Interest coverage x1,305.51.7 78,677.8%   
Debt to equity ratio x00.9 0.1%  
Sales to assets ratio x0.50.1 364.7%   
Return on assets %9.811.1 87.7%  
Return on equity %13.419.4 69.3%  
Return on capital %20.410.3 198.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2215,110 0.1%   
Fx outflow Rs m1,4894,298 34.6%   
Net fx Rs m-1,46610,813 -13.6%   
CASH FLOW
From Operations Rs m3,318-159,666 -2.1%  
From Investments Rs m-2,383-17,677 13.5%  
From Financial Activity Rs m-1,104186,503 -0.6%  
Net Cashflow Rs m-1699,364 -1.8%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 4.0 187.5%  
FIIs % 4.9 26.6 18.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 16.5 143.6%  
Shareholders   85,207 93,274 91.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

The BSE HEALTHCARE Index Down 2% ; VIVIMED LABS LTD Among Top Losers (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

The BSE HEALTHCARE Index Down at 16,043 (down 2.3%). Among the top losers in the BSE HEALTHCARE Index today are VIVIMED LABS LTD, VIMTA LABS and RPG LIFE SCIENCES. Meanwhile, the BSE Sensex has plunged 0.7% to 37,489.

IPCA LABS Plunges by 6%; BSE HEALTHCARE Index Down 1.8% (Market Updates)

Sep 21, 2018 | Updated on Sep 21, 2018

IPCA LABS share price has plunged by 6% and its current market price is Rs 755. The BSE HEALTHCARE is down by 1.8%. The top gainers in the BSE HEALTHCARE Index are SANOFI INDIA (up 3.8%) and ERIS LIFESCIENCES LIMITED (up 3.6%). The top losers are IPCA LABS (down 5.9%) and PIRAMAL ENTERPRISES (down 5.3%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 21, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS